Vital Signs - Smoking Cessation - A Changing Industry with Enormous Opportunities


USD 1,500.00

* Required Fields

USD 1,500.00


Be the first to review this product

This issue of Vital Signs, released on July 9, 2007, provides a strategic overview of issues surrounding the development and marketing of treatments for smoking cessation. Additionally, a company spotlight is provided for Alkermes, Inc., a leader in drug delivery technologies. Reimbursement and regulatory news from the FDA is also provided for June 25 - June 29, 2007.

Table of Contents

Vital Signs - Smoking Cessation - A Changing Industry with Enormous OpportunitiesVital Signs: 9 July 2007This week's issue:

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.